Regulus Therapeutics Inc.
RGLS
$7.86
-$0.01-0.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -79.50% | 3,166.99% | |||
| Gross Profit | 79.50% | -3,166.99% | |||
| SG&A Expenses | -8.71% | 5.46% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -23.34% | -9.63% | |||
| Operating Income | 23.34% | 9.63% | |||
| Income Before Tax | 24.68% | 9.04% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 24.68% | 9.04% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 24.68% | 9.04% | |||
| EBIT | 23.34% | 9.63% | |||
| EBITDA | 23.47% | 9.66% | |||
| EPS Basic | 25.45% | 9.08% | |||
| Normalized Basic EPS | 25.47% | 9.02% | |||
| EPS Diluted | 25.45% | 9.08% | |||
| Normalized Diluted EPS | 25.47% | 9.02% | |||
| Average Basic Shares Outstanding | 1.03% | 0.04% | |||
| Average Diluted Shares Outstanding | 1.03% | 0.04% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||